Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Maduck Sean 2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) See Remarks (Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY 3. Date of Earliest Transaction (Month/Day/Year) 09/02/2025 (Street) REDWOOD CITY, CA 94065 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/02/2025 M 20,000 A $5.05 27,681(1) D Common Stock 09/02/2025 S(2) 15,070 D $70.3787(3) 12,611(1) D Common Stock 09/02/2025 S(2) 4,930 D $70.8359(4) 7,681(1) D Common Stock 09/02/2025 A 228(5) A $71.38(6) 7,909(1) D Common Stock 09/02/2025 A 228(7) A $ 0 8,137(1) D Common Stock 09/03/2025 F(8) 233 D $71.38(9) 7,904(1) D Common Stock 59,717 I See Footnote(10) Common Stock 40,000 I See Footnote(11) Common Stock 10,000 I See Footnote(12)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock option (right to buy)

$5.05

09/02/2025

M

20,000

(13)

05/02/2026

Common Stock

20,000

$ 0

1,986

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY, CA 94065			See Remarks

Signatures

/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck		09/04/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
(2)	This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
(3)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.715 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(4)	Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.72 to $71.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
(5)	The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.
(6)	In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
(7)	Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
(8)	These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
(9)	The closing price on September 2, 2025 was used to calculate the withholding obligation.
(10)	Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
(11)	Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
(12)	Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
(13)	Fully exercisable.
Remarks: President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.